drugset / Trial / NCT00782769

A Safety Extension Study of DR-OXY-301

NCT00782769 ↗

Phase 3 Completed 240 enrolled Duramed Research
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a safety extension study of DR-OXY-301 at pre-selected sites. Subjects who complete the DR-OXY-301 study are eligible to participate. The duration of this extension study will be up to approximately 42 weeks. Subjects will have physical and laboratory exams, including blood draws at each scheduled visit and colposcopic examination of the vagina and cervix. As in DR-OXY-301, subjects will be required to insert a vaginal ring; replacing it every 4 weeks. Subjects will also be required to keep a daily record of the number of times and the total amount of time the ring was outside the body each day and the reason for voluntary removal.

Timeline

Start
2008-09
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxybutinyn Unknown 4 mg Other
Subject Oxybutinyn Unknown 6 mg Other

Indications